Clinical And Translational Study Of MK-2206 In Patients With Metastatic KRAS-Wild-Type, PIK3CA-Mutated, Colorectal Cancer
A Phase II Clinical And Translational Study Of MK-2206 In Patients With Metastatic KRAS-Wild-Type, PIK3CA-Mutated, Colorectal Cancer
Sponsor: Memorial Sloan Kettering Cancer Center
Terminated
Lack of accrual
Other terminated trials from Memorial Sloan Kettering Cancer Center
- Sarcoma · Phase PHASE2 · Jul 2024
- Acute Lymphoid Leukemia (ALL) · Phase PHASE2 · Mar 2024
- Gynecologic Surgery · Phase NA · Dec 2023
- Prostate Cancer · Phase PHASE2 · Jul 2023
- Diffuse Large B-Cell Lymphoma and Follicular Lymphoma · Phase PHASE1/PHASE2 · May 2023
See all terminations from Memorial Sloan Kettering Cancer Center
A PHASE2 clinical study on Colon Cancer and Rectal Cancer, this trial is terminated or withdrawn. The trial is conducted by Memorial Sloan Kettering Cancer Center and has accumulated 9 data snapshots since 2010. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE2
-
Jun 2022 — Dec 2022 [monthly]
Terminated PHASE2
▶ Show 4 earlier versions
-
Jan 2021 — Jun 2022 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Aug 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Memorial Sloan Kettering Cancer Center
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .